17 Rosenstock, J., et al., Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
[148] found that the dipeptide l-alanyl-l-glutamine administration provided a beneficial ergogenic effect by increasing time to exhaustion following a mild hydration stress, and the effects were linked to an enhanced fluid and electrolyte absorption
Karl Nadolsky, DO, Assistant Clinical Professor at Michigan State University College of Human Medicine and Director of the Endocrine Clinic at the Gym, says there is a paradigm shift toward the quality and kind of weight loss versus a focus on the amount of weight lost
Transitioning to Branded Medications If Hims exits compounding, a viable alternative would be to distribute FDA-approved branded GLP-1 drugs approved for weight loss, like Mounjaro or Wegovy
A 510 pound loss over twelve weeks demonstrates that semaglutide is suppressing your appetite and creating a calorie deficit
Kersthold M, et al
